Journal of the American College of Cardiology Vol. 59, No.

23, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.035

2-Hour Accelerated Diagnostic Protocol to Assess

Patients With Chest Pain Symptoms Using
Contemporary Troponins as the Only Biomarker
The ADAPT Trial
Martin Than, MB, BS,*† Louise Cullen, MB, BS,‡§ Sally Aldous, MB, CHB, MD,*
William A. Parsonage, DM,‡储 Christopher M. Reid, PHD,¶ Jaimi Greenslade, PHD,‡储
Dylan Flaws, BA, MSC,储 Christopher J. Hammett, MB, CHB, MD,‡ Daren M. Beam, MD,#
Michael W. Ardagh, MB, CHB, DCH, PHD,† Richard Troughton, MB, CHB, PHD,*†
Anthony F. T. Brown, MB, CHB,‡储 Peter George, MB, BS,* Christopher M. Florkowski, MB, BS,*
Jeffrey A. Kline, MD,# W. Frank Peacock, MD,** Alan S. Maisel, MD,†† Swee Han Lim, MB, BS,‡‡
Arvin Lamanna, MB, BS,‡ A. Mark Richards, MD, PHD†
Christchurch, New Zealand; Brisbane and Melbourne, Australia; Charlotte, North Carolina;
Cleveland, Ohio, San Diego, California; and Singapore

Objectives The purpose of this study was to determine whether a new accelerated diagnostic protocol (ADP) for possible cardiac
chest pain could identify low-risk patients suitable for early discharge (with follow-up shortly after discharge).

Background Patients presenting with possible acute coronary syndrome (ACS), who have a low short-term risk of adverse
cardiac events may be suitable for early discharge and shorter hospital stays.

Methods This prospective observational study tested an ADP that included pre-test probability scoring by the Thrombolysis
In Myocardial Infarction (TIMI) score, electrocardiography, and 0 ⫹ 2 h values of laboratory troponin I as the sole
biomarker. Patients presenting with chest pain due to suspected ACS were included. The primary endpoint was
major adverse cardiac event (MACE) within 30 days.
Results Of 1,975 patients, 302 (15.3%) had a MACE. The ADP classified 392 patients (20%) as low risk. One (0.25%) of these pa-
tients had a MACE, giving the ADP a sensitivity of 99.7% (95% confidence interval [CI]: 98.1% to 99.9%), negative predictive
value of 99.7% (95% CI: 98.6% to 100.0%), specificity of 23.4% (95% CI: 21.4% to 25.4%), and positive predictive value of
19.0% (95% CI: 17.2% to 21.0%). Many ADP negative patients had further investigations (74.1%), and therapeutic (18.3%)
or procedural (2.0%) interventions during the initial hospital attendance and/or 30-day follow-up.

Conclusions Using the ADP, a large group of patients was successfully identified as at low short-term risk of a MACE and therefore
suitable for rapid discharge from the emergency department with early follow-up. This approach could decrease the
observation period required for some patients with chest pain. (An observational study of the diagnostic utility of an accel-
erated diagnostic protocol using contemporary central laboratory cardiac troponin in the assessment of patients presenting
to two Australasian hospitals with chest pain of possible cardiac origin; ACTRN12611001069943) (J Am Coll Cardiol
2012;59:2091–8) © 2012 by the American College of Cardiology Foundation

From the *Christchurch Hospital, Christchurch, New Zealand; †University of Otago, Endocrine Research Group and the Queensland Emergency Medicine Research Foun-
Christchurch, New Zealand; ‡Royal Brisbane and Women’s Hospital, Brisbane, dation with small (20%) contributions from industry (Abbott and Alere). Drs. Than,
Australia; §University of Technology, Brisbane, Australia; 储University of Queensland, Cullen, and Parsonage, and Prof. Richards and Prof. Peacock have accepted travel,
Brisbane, Australia; ¶Monash University, Melbourne, Australia; #Carolinas Medical accommodation, consulting fees, or honoraria from Abbott. All other authors have
Centre, Charlotte, North Carolina; **Cleveland Clinic Foundation, Cleveland, Ohio; reported that they have no relationships relevant to the contents of this paper to disclose.
††University of California, San Diego, California; and the ‡‡Singapore General Hospital, Manuscript received December 23, 2011; revised manuscript received February 13,
Singapore. Funding for the study was predominantly from the Christchurch Cardio- 2012, accepted February 14, 2012.
2092 Than et al. JACC Vol. 59, No. 23, 2012
Rapid Assessment of Possible Cardiac Chest Pain June 5, 2012:2091–8

Abbreviations A missed diagnosis of acute coro- ED patients suspected of having ACS who are suitable for
and Acronyms nary syndrome (ACS) may lead to safe early discharge. These patients could then have early
further ischemic events and a poten- outpatient or accelerated in-patient follow-up.
ACS ⴝ acute coronary
syndrome(s) tially preventable death or disability.
ADP ⴝ accelerated
Therefore, patients with symptoms
diagnostic protocol suggestive of ACS often undergo a Methods
AMI ⴝ acute myocardial
lengthy assessment in the emer-
Study design and setting. The ADAPT (2-Hour Accel-
infarction gency department (ED) or as hospi-
erated Diagnostic Protocol to Assess Patients With Chest
cTn ⴝ cardiac troponin tal inpatients. These patients ac-
Pain Symptoms Using Contemporary Troponins as the
cTnI ⴝ cardiac troponin I
count for approximately 10% of ED
Only Biomarker) trial was a prospective observational vali-
ECG ⴝ electrocardiography
See page 2099
dation study designed to assess a predefined ADP that
ED ⴝ emergency consisted of TIMI score risk assessment, ECG, and 0- and
department 2-h central laboratory contemporary cardiac troponin I
presentations and 25% of hospital
HS-cTn ⴝ highly sensitive (cTnI) as the only biomarker. The study population was
cardiac troponin admissions (1), yet up to 85% do not
from the Brisbane, Australia and Christchurch, New Zea-
MACE ⴝ major adverse
have a final diagnosis of ACS (2–4).
land, that is, 2 of the 14 sites participating in the ASPECT
cardiac event(s) Prolonged assessment contributes to
study. Most participants were recruited as part of the
STEMI ⴝ ST-segment
duplication of work, high costs, and
ASPECT trial, but we also included additional patients
elevation myocardial ED overcrowding, which leads to
infarction adverse patient outcomes, including through ongoing post-ASPECT recruitment at both cen-
increased mortality (1,5). The need ters. The process for 2-h blood sampling and central
TIMI ⴝ Thrombolysis In
Myocardial Infarction for accurate identification of a low- laboratory analysis of cTnI was pre-planned before the start
risk group that may be safely dis- of the ASPECT study, and a priori local ethics committee
charged without jeopardy of an adverse event from an ACS is approval was obtained for this. All participants provided
written informed consent. The results of the 2-h cTnI
therefore a priority (4).
samples were not used as part of routine clinical care (or for
International guidelines for the investigation of ACS rec-
reference standard adjudication). This study was subse-
ommend serial measurement of cardiac troponin (cTn) at the
quently separately registered with the Australia-New Zea-
onset of symptoms, and many hospitals use the presentation
land Clinical Trials Registry, ACTRN12611001069943.
at the ED as time zero for sampling (6 –10). A reproducible,
Participants. Patients were enrolled consecutively between
reliable, and more timely process for identifying patients
November 2007 and February 2011, at 2 urban EDs in
presenting with chest pain who have a low short-term risk
Brisbane, Australia and in Christchurch, New Zealand. Due
of adverse cardiac events is needed to support their earlier
to local recruitment logistics, enrollment did not start and
discharge (4). Only 2 studies have prospectively validated
finish at the same time in each center. Criteria for enroll-
accelerated diagnostic protocols (ADPs) for the early dis- ment included age ⱖ18 years of age, with at least 5 min of
charge of low-risk patients using serial biomarkers in the symptoms consistent with ACS, where the attending phy-
first 2 hours after arrival (11,12). sician planned to perform serial cTn tests. The American
The recent ASPECT (A 2-h Diagnostic Protocol to Heart Association case definitions for possible cardiac
Assess Patients with Chest Pain Symptoms in the Asia- symptoms were used (i.e., acute chest, epigastric, neck, jaw,
Pacific region) study used 0- and 2-h biomarker testing with or arm pain; or discomfort or pressure without an apparent
a point-of-care multimarker panel, electrocardiography noncardiac source) (14). Patients were excluded for any of
(ECG), and the Thrombolysis In Myocardial Infarction the following: ST-segment elevation myocardial infarction
(TIMI) score (11). In that study, the ADP identified 9.8% (STEMI), a clear cause other than ACS for the symptoms
of patients with suspected ACS who could have been (e.g., examination findings of varicella zoster), inability to
discharged early from the ED, with a sensitivity of 99.3% provide informed consent, staff considered recruitment to be
for 30-day major adverse cardiac events (MACE). inappropriate (e.g., receiving palliative treatment), transfer
Some studies have shown superiority of point-of-care mul- from another hospital, pregnancy, previous enrollment, or
timarker strategies compared with troponin alone when used inability to be contacted after discharge. Perceived high risk
for early evaluation of such patients, but studies have been was not used as an exclusion criterion. Patients were
criticized for using relatively insensitive cTn assays. Current managed according to local hospital protocols, including
laboratory troponins may now be equivalent or superior to point- blood draws for cTnI measurement at presentation, and
of-care multimarker strategies even at these early time points (13). then 6 to 12 h afterwards in compliance with international
This might increase the number of patients eligible for early guidelines (6,14). Christchurch Hospital used the Abbott
discharge, while maintaining very high sensitivity (⬎99%). ARCHITECT cTnI assay (Abbott, Inc., Chicago, Illinois),
The purpose of this study was to determine if an ADP which has a detection limit of ⬍0.01 ␮/l, 99th percentile of
using a serial troponin as the only biomarker could identify 0.028 ␮/l, 10% coefficient of variation of 0.032 ␮/l, and a
JACC Vol. 59, No. 23, 2012 Than et al. 2093
June 5, 2012:2091–8 Rapid Assessment of Possible Cardiac Chest Pain

decision cutoff, as per manufacturer, of ⬎0.030 ␮/l. Royal The ADAPT

Table 1 ADP
The ADAPT ADP
Brisbane and Women’s Hospital used the DxI Access Accu
cTnI assay (Beckman Coulter, Chaska, Minnesota), which All parameters had to be negative for the ADP to be considered negative and for
has a detection limit of 0.01 ␮/l, 99th percentile of 0.04 ␮/l, the patient to be identified as low-risk

10% coefficient of variation of 0.06 ␮/l, and a decision 1. cTnI level at 0 and 2 h below institutional cutoff for an elevated troponin
concentration
cutoff, as per manufacturer, of ⬎0.04 ␮/l. Following Federal
2. No new ischemic changes on the initial ECG
Drug Authority concerns about results consistency between 3. TIMI score ⫽ 0 (16)
DxI analyzers for measurement of the Beckman assay, a a. Age ⱖ65 yrs
local reassessment was performed in Brisbane that showed b. Three or more risk factors for coronary artery disease:
only a 5% bias between the 2 local DxI analyzers. Long- (family history of coronary artery disease, hypertension,
term imprecision at the 99th percentile has been 13% to hypercholesterolaemia, diabetes, or being a current smoker)

14%. After assessment of local data, there has been no c. Use of aspirin in the past 7 days
d. Significant coronary stenosis (e.g., previous coronary stenosis ⱖ50%)
market withdrawal in Australasia. In both centers, results
e. Severe angina (e.g., ⱖ2 angina events in past 24 h or persisting
for clinical use and outcomes adjudication were rounded to discomfort)
2 decimal places. f. ST-segment deviation of ⱖ0.05 mV on first ECG
Data were collected prospectively using a published data g. Increased troponin and/or creatine kinase-MB blood tests
dictionary (15). Nursing staff collected the demographic and (during assessment*)

clinical data from patients, supervised ECG testing, and *The results of the 0-h cardiac troponin-I (cTnI) were used for calculation of the Thrombolysis In
drew blood samples for cTnI testing. If a patient was unsure Myocardial Infarction (TIMI) score in this study, which is a modification from the original published
score. This score parameter and that of ST-segment deviation are effectively redundant in the
of an answer to a question (e.g., history of hypertension), a ADAPT accelerated diagnostic protocol (ADP) because of the broader cTnI and electrocardiographic
response of “No” was recorded. Patients were followed up to (ECG) criteria (1 and 2).

determine the occurrence of MACEs within 30 days of

presentation, at 45 days, and after 1 year using all of: (including the initial hospital attendance). An adverse event
1) telephone contact by research staff; 2) review of patients’ included: death (unless clearly noncardiac), cardiac arrest,
hospital notes; and 3) a national health events search (which emergency revascularization procedure, cardiogenic shock,
identifies any death). Data were also recorded regarding the use ventricular arrhythmia needing intervention, high-degree
of further testing for ACS (e.g., stress testing or imaging) and atrioventricular block needing intervention, and acute myocar-
interventions (therapeutic or procedural) within 30 days. The dial infarction (AMI) (Online Table 1). AMI was classified
Centre for Clinical Research Excellence, Monash University, using the global taskforce recommendations requiring
Melbourne, Australia, independently undertook data coordi- evidence of myocardial necrosis together with clinical
nation, monitoring, analysis, and source verification. evidence of myocardial ischemia (ischemic symptoms,
Index test. The predefined ADP under investigation con- ECG changes, or imaging evidence) (8). Necrosis was
sisted of a TIMI risk score of 0 at presentation (16), no diagnosed on the basis of a rising or falling pattern (a
ischemic changes on the initial ECG (i.e., not known to be delta of ⱖ20% was used) of the laboratory troponin
pre-existing), and central laboratory cTnI concentrations (at
concentrations, with at least 1 value above the decision
0 and 2 h after arrival) below the institutional cutoff used to
cutpoint (99th percentile, at a level of assay imprecision
indicate troponin elevation (Table 1). For a patient to be
near 10%). The cTnI results from blood draws at presenta-
identified as low risk, all parameters in the ADP had to be
tion, and after 6 to 12 h (i.e., from routine care) were used
negative.
for determination of necrosis. If the cTnI concentration was
Patients with ischemic ECG changes and no evidence
elevated, but a ⬍20% rise or fall was recorded, then other
that they were pre-existing, were defined as high risk. ECG
changes were defined as ST-segment depression of at least causes of a raised troponin concentration were actively
0.05 mV in ⱖ2 contiguous leads (including reciprocal pursued by the adjudicators. If no clear alternative cause of
changes), T-wave inversion of at least 0.1 mV, or Q waves the troponin rise was evident, and if the clinical presentation
⬎30 ms in width and ⱖ0.1 mV in depth in at least 2 was suggestive of an ACS, an adjudicated diagnosis of AMI
contiguous leads (15,17–19). Patients with other abnormal was decided.
ECG findings (e.g., pacing artifact and left bundle branch Statistical analysis. Baseline characteristics of the partici-
block) that were present on pre-existing ECGs were not pants were analyzed with conventional group descriptive sta-
defined as high risk. tistics. For continuous variables, mean ⫾ SD were calculated,
Central laboratory cTnI concentrations (at 0 and 2 h after whereas for categorical data, the proportions in each of the
arrival) above the institutional cutoff were used to indicate ADP positive and negative groups were reported. The sensi-
cTnI elevation. The same troponin assays and cutoffs were tivity, specificity, and positive and negative predictive values for
used to indicate cTnI elevation as for standard care at each hierarchical primary and secondary events were generated
institution (as described previously). using chi-square analyses for the ADP as a whole and its
Reference standard. The primary endpoint was a composite constituents individually or in combination. Sensitivities were
of MACEs that occurred within 30 days after first presentation compared using the McNemar test.
2094 Than et al. JACC Vol. 59, No. 23, 2012
Rapid Assessment of Possible Cardiac Chest Pain June 5, 2012:2091–8

Figure 1 Participant Recruitment Flowchart

The 193 patients eligible, but not recruited, were similar in age, gender, and risk factors (p ⬎ 0.05 for all). The 30-day follow-up included initial hospital attendance,
and no patients were lost to follow-up. ADP ⫽ accelerated diagnostic protocol; MACE ⫽ major adverse coronary event(s); TIMI ⫽ Thrombolysis In Myocardial Infarction.

Results angiography and stenting for right coronary and circum-

flex artery stenosis. The patient had no further cardiac
Patient characteristics. There were 1,975 consenting, eli-
gible patients suitable for analysis (Fig. 1). No patients were problems during 1 year of follow-up.
lost to 30-day follow-up. Participants were predominantly A secondary analysis using a TIMI score of 0 or 1 (as
Caucasian, older men who commonly had risk factors for opposed to TIMI 0) in the ADP resulted in 38.4% of
coronary artery disease; the cohort had a significant rate of patients being categorized as low risk, but with 9 false
known coronary artery disease (Table 2). negative results for the primary outcome, giving a sensi-
A total of 302 patients (15.3%) had a primary outcome tivity of 97.0%, negative predictive value of 98.8%,
event within 30 days, with most occurring within the first specificity of 44.8%, and positive predictive value of
10 days. The majority of these events (15.1%) were 24.1%.
myocardial infarctions (Table 3). The ADP identified Individual diagnostic parameters were not as effective at
392 patients (20%) as low risk of a MACE within 30 days identifying patients who had a MACE compared with
(Table 4). when these parameters were used together (Tables 4 and 5).
Diagnostic accuracy. Table 5 presents the statistical anal- The combination of TIMI score and ECG without 0- and
ysis of the ADP and its parameters for predicting 2-h troponin failed to identify 5 patients with a MACE at
MACEs within 30 days. Only 1 (0.25%) patient, classi- 30 days. Using the ADP, 4 of these 5 patients were correctly
fied as low risk by the ADP, had a MACE during initial identified with a reduction in the number of false negatives
hospital attendance and follow-up. This patient was a to 1 (Fig. 2). The ADP identified a larger proportion of
52-year-old Caucasian male who presented after 3.5 h of patients as low risk in participants presenting early after the
chest pain. He was previously healthy, with no risk onset of symptoms (0 to 3 h) than among those presenting
factors for ischemic heart disease. He had a normal ECG later (Online Table 1).
and his Abbott troponin I was ⬍0.01 ␮g/l at 0 h, 0.03 The majority of ADP negative patients (316 of 392
␮g/l at 2 h, and 16.8 ␮g/l after 12 h. He underwent [74.1%]) had further investigations within 30 days, and most of
JACC Vol. 59, No. 23, 2012 Than et al. 2095
June 5, 2012:2091–8 Rapid Assessment of Possible Cardiac Chest Pain

Demographics:
Table 2 Participant Characteristics
Demographics: Participant Characteristics

Total
Characteristics (Nⴝ1,975) ADP Positive ADP Negative
Demographics
Age, yrs 60.4 ⫾ 14.9 63.2 ⫾ 14.8 49.4 ⫾ 9.2
Sex (% male) 60.0 (1,185) 60.1 (951) 59.7 (234)
Ethnicity*
Caucasian 89.8 (1,748) 90.3 (1,411) 87.5 (337)
Maori 1.7 (34) 1.9 (30) 1.0 (4)
Aboriginal 0.8 (16) 0.8 (13) 0.8 (3)
Indian 0.9 (17) 0.8 (13) 1.0 (4)
Chinese 0.2 (3) 0.2 (3) 0 (0)
Other 6.8 (129) 6.0 (92) 9.6 (37)
Risk factors
Hypertension 52.1 (1,029) 59.0 (934) 24.2 (95)
Diabetes 14.4 (285) 17.4 (276) 2.3 (9)
Dyslipidemia 51.1 (1,009) 57.5 (907) 26.1 (102)
Smoking
Previous smoker 41.7 (823) 43.5 (688) 34.5 (135)
Current smoker 18.9 (374) 18.3 (289) 21.7 (85)
Family history of coronary artery disease 53.5 (1,056) 55.4 (874) 46.4 (182)
Medical history
Angina 33.8 (668) 41.5 (657) 2.8 (11)
Coronary artery disease 21.0 (415) 26.2 (414) 0.3 (1)
Acute myocardial infarction 23.3 (461) 29.1 (461) 0 (0)
Revascularization 17.3 (341) 21.7 (341) 0 (0)
Congestive heart failure 7.9 (157) 9.8 (155) 0.5 (2)
Stroke 9.6 (190) 11.6 (183) 1.8 (7)
Coronary artery bypass graft 8.7 (172) 10.9 (172) 0 (0)
Arrhythmia 6.1 (121) 7.4 (116) 1.3 (5)
Length of initial hospital attendance (h)
Median 31.3 (24–96) 48.0 (24–120) 24.1 (11.3–28.1)
Mean 81.8 ⫾ 245.2 93.1 ⫾ 270.8 34.8 ⫾ 48.2

Values are mean ⫾ SD, % (n), or median (interquartile range [IQR]). *Data missing in 28 patients. Values ⬎100% due to multiple factors reported
by patients.

these investigations were stress tests (81.1%) and occurred Discussion

during the initial hospital attendance (88.0%). Investigations
generally occurred within a median timeframe of approxi- This large 2-center Australasian study prospectively vali-
mately 7 days (Online Table 2a). Therapeutic and procedural dated a 2-h ADP incorporating ECG, TIMI score, and
interventions occurred in 18.3% and 2.0% of ADP negative cTnI. With use of this ADP, a large group (20%) of patients
patients, respectively (Online Table 2b). presenting with possible ACSs was identified as low risk

During Initial
Frequency andHospital
Type ofAttendance
Frequency Major Adverse
and Type oforMajor
30-Day
Cardiac
Follow-Up
Event
Adverse Cardiac Event
Table 3
During Initial Hospital Attendance or 30-Day Follow-Up

Percentage of Patients Percentage Frequency of

No. of Events Who Had Event Type Event Type of Total Patients
Major Adverse Cardiac Event (n ⴝ 350) (n ⴝ 302) (N ⴝ 1,975)
Non–STEMI 273 90.40 13.82
STEMI 25 8.28 1.27
Emergency revascularization 26 8.61 1.32
Cardiovascular death 8 2.65 0.41
Ventricular arrhythmia 6 1.99 0.30
Cardiac arrest 3 0.99 0.15
Cardiogenic shock 4 1.32 0.20
High atrioventricular block 5 1.66 0.25

ST-segment elevation myocardial infarction (STEMI) occurred after initial recruitment. *350 events occurred in 302 patients during initial hospital
attendance or 30-day follow-up.
2096 Than et al. JACC Vol. 59, No. 23, 2012
Rapid Assessment of Possible Cardiac Chest Pain June 5, 2012:2091–8

Follow-Up
Test Parameter
According
TestPerformance:
to the Results
Parameter Occurrence
of Individual
Performance: of Major
and
Adverse
Occurrence Combination
Cardiac
of Major ofEvents
the Cardiac
Adverse Accelerated
During Initial
Diagnostic
Events Hospital
During Protocol
Attendance
Initial Testor
Hospital Parameters
30-Day or 30-Day
Attendance
Table 4
Follow-Up According to the Results of Individual and Combination of the Accelerated Diagnostic Protocol Test Parameters

Outcome Outcome

Test MACE No MACE Total Test MACE No MACE Total

ECG* Troponin†
Positive 74 193 267 Positive 264 124 388
Negative 228‡ 1,480 1,708 Negative 38‡ 1,549 1,587
Total 302 1,673 1,975 Total 302 1,673 1,975
TIMI§ ECG ⫹ troponin储
Positive 293 1,238 1,531 Positive 269 291 560
Negative 9‡ 435 444 Negative 33‡ 1,382 1,415
Total 302 1,673 1,975 Total 302 1,673 1,975
ECG ⫹ TIMI¶ ADP (ECG ⫹ TIMI* ⫹ troponin)#
Positive 297 1,280 1,577 Positive 301 1,282 1,583
Negative 5‡ 393 398 Negative 1‡ 391 392
Total 302 1,673 1,975 Total 302 1,673 1,975

*Electrocardiography (ECG) alone: any new ischemia was positive. †Any cardiac troponin-I (cTnI) greater than the cutoff was positive. ‡Accelerated diagnostic protocol (ADP) false negative cases.
§Thrombolysis In Myocardial Infarction (TIMI) score of ⱖ1 was positive. TIMI used contemporary cTnI and ECG result at 0 h. 储cTnI more than the cutoff or any new ischemia on ECG was positive. ¶Any new
ischemia on ECG or TIMI score ⱖ1 was positive. #ADP was negative if TIMI score was 0 and ECG and cTnI were all negative. If TIMI score was ⱖ1 or any other parameter was positive, then ADP was positive.
MACE ⫽ major adverse cardiac event.

and suitable for outpatient care at a risk of 0.25% for a mended value of greater than the 99th percentile (rather
short-term MACE. These patients could have been safely than using the local institution’s cutoff rounded to 2 decimal
discharged to outpatient follow-up many hours earlier than places), the sensitivity of this ADP would have been
what usually occurs in current practice. The reduction in unchanged (99.7%). Using such a cutoff would have iden-
time required for observation for some patients through tified 3 less patients (n ⫽ 389; 19.7%) as low risk (Online
application of this ADP could have significant benefits for Table 3).
health services, even in those centers with chest pain This study confirms that each of the components of the
observation units. In the United States alone, ⬎6 million ADP, including troponin, is needed to achieve sufficient
ED visits a year involve patients presenting with chest pain sensitivity to be used at an early timeframe after presenta-
(20). In centers with lower disease prevalence, such as in the tion (Table 4). A TIMI score equaling 0 within the ADP
United States, it is likely that even more patients would be resulted in a lower and more acceptable false negative rate
suitable for discharge to outpatient care with this ADP,
than when only troponins and ECG were used for the
which could potentially reduce extended observation in
prediction of 30-day MACEs (0.25% vs. 3.2%).
millions of patients annually. In patients unsuitable for
This study also demonstrates that central laboratory
outpatient follow-up, a negative ADP result could allow
troponin assays currently in use have sufficient sensitivity at
earlier in-patient investigation and still reduce length of stay
in the hospital. an early time point to negate the need for additional
The new ADP has a very high sensitivity and negative biomarkers (such as myoglobin and creatine kinase-MB) as
predictive value, and using a contemporary cTnI as the components of the ADP. These other biomarkers do not
single biomarker in the ADP doubled the proportion of improve the sensitivity, and reduce the proportion of pa-
patients classified as low risk in comparison to the ASPECT tients defined as low risk (due to a greater number of
study (20% vs. 9.8%) (11). If the cutoff used to define an patients with a positive biomarker result), as was shown in
elevated troponin had been the internationally recom- the ASPECT study (11).

Diagnostic
Table 5 Accuracy:
DiagnosticAccuracy of Accuracy
Accuracy: cTnI, ECG,ofTIMI,
cTnI,and ADP
ECG, for and
TIMI, Prediction
ADP forofPrediction
MACE of MACE

ECG ECG* Troponin† Troponin and ECG‡ TIMI and ECG§ ADP (ECGⴙ TIMI ⴙ Troponin)储
Sensitivity 24.5 (20.0–29.7) 87.4 (83.2–90.7) 89.1 (85.1–92.1) 98.3 (96.2–99.3) 99.7 (98.1–99.9)
Negative predictive value 86.7 (85.0–88.2) 97.6 (96.7–98.3) 97.7 (96.7–98.3) 98.7 (97.1–99.5) 99.7 (98.6–100.0)
Specificity 88.5 (86.8–89.9) 92.6 (91.2–93.7) 82.6 (80.7–84.3) 23.5 (21.5–25.6) 23.4 (21.4–25.5)
Positive predictive value 27.7 (22.7–33.4) 68.0 (63.2–72.5) 48.0 (43.9–52.2) 18.8 (17.0–20.8) 19.0 (17.2–21.0)
Negative likelihood ratio 0.85 (0.80–0.91) 0.14 (0.10–0.18) 0.13 (0.10–0.18) 0.07 (0.03–0.17) 0.01 (0.002–0.10)
Positive likelihood ratio 2.12 (1.67–2.70) 11.79 (9.90–14.05) 5.12 (4.58–5.72) 1.29 (1.25–1.33) 1.30 (1.27–1.34)

*ECG alone: any new ischemia was positive. †cTnI more than cutoff for an elevated troponin was positive. ‡Troponin and ECG: cTnI more than cutoff value for an elevated troponin and/or any new ischemia
on ECG was positive. §TIMI and ECG: TIMI score of ⱖ1 was positive and/or any new ischemia on ECG was positive. 储ADP was negative if TIMI score was 0 and ECG and troponin were all negative. If TIMI
score was ⱖ1 or any other parameter was positive, then ADP was positive.
Abbreviations as in Table 4.
JACC Vol. 59, No. 23, 2012 Than et al. 2097
June 5, 2012:2091–8 Rapid Assessment of Possible Cardiac Chest Pain

planned to investigate. In particular, the inclusion of pre-

dominantly Caucasian patients may restrict the interna-
tional generalizability of these findings. Patients who pre-
sented with atypical symptoms without chest pain were not
included in this trial, and deciding when to investigate these
for an ACS remains a challenge.
The study was an observational study and not an inter-
vention study. Ideally, a randomized controlled trial of the
diagnostic protocol would now occur. However, in practice,
such studies are rare. As a result of the observational design,
most ADP negative patients had further investigations and
some treatments as in-patients (Online Tables 2a and 2b).
Hospital admission, investigation, and subsequent treat-
ment (e.g., revascularization, antiplatelet, or antithrombotic
therapy) were common and possibly secured better out-
comes. Thus, patients who are ADP negative require
further nonurgent follow-up investigations and possibly
treatment. In some health systems, it will be possible for
Figure 2 ADP Component False Negatives these investigations to occur rapidly on an outpatient basis,
and where this is not possible, a negative ADP result could
Occurrence of major adverse cardiac event during initial hospital attendance or
30-day follow-up in patients with negative results for individual and combina- allow earlier progression to in-patient investigation and still
tions of diagnostic parameters (values refer to numbers of patients). ECG ⫽ reduce length of stay in the hospital.
electrocardiography; other abbreviations as in Figure 1.
The sensitivity of the ADP appears to be high. HS-cTn
assays appear to detect and predict additional adverse
outcomes compared with conventional assays. It is possible
The results show that the ADP is sensitive for both early
that if an HS-cTn assay was used as the reference standard
and late presenters, identifying a greater proportion of
troponin at arrival and after 6⫹ h, then this would lead to
patients as low risk in early presenters. Thus, the ADP
a greater number of patients being classified as having a
could have the greatest impact in patients presenting within
non-STEMI and, therefore, maybe a lower sensitivity. This
3 h of symptom onset, the group in which the second
potential limitation is always a possibility when changing
troponin sampling time point is usually most delayed.
technology creates a more sensitive reference standard. It is
Body et al. (21) described how a highly sensitive cTn
(HS-cTn) assay may allow early “rule-out” of AMI using a also possible that by using HS-cTn assays, some patients
blood test only on arrival. Their study utilized the assay level with negative results may be able to avoid, or have less
of detection rather than the 99th percentile. Highly sensi- extensive follow-up investigations after ED assessment than
tive assays are not yet widely available, but if prospectively occurred in this cohort of patients. This requires further
validated, then this approach may be important. However, evaluation. The purpose of this study was to show that an
when early results are used in conjunction with the TIMI ADP could use the same 2 troponin assays as currently used
risk score and ECG, sensitivity may not be significantly at our hospitals to identify a group of patients as very low
improved and specificity may be reduced. It is not yet clear risk at an earlier time point than usual. The specificity
how early after presentation we can rely on negative highly (23.5%) of our method might be regarded as a limitation,
sensitive troponin results alone without requiring other but as a “rule-out” rather than a “rule-in” tool, this speci-
clinical data such as the TIMI score. Further work is also ficity is a significant improvement compared with other
needed to guide the interpretation and management of the pathways (11). Patients who are not low risk according to
increased number of patients with a positive troponin result the ADP should continue to be managed with existing
that occur using highly sensitive troponin assays. Other clinical care that involves extended observation or admis-
biomarkers, such as copeptin and heart fatty acid binding sion. A process yielding a higher specificity could discharge
protein, may improve the baseline sensitivity for AMI; a larger number of patients, but at the cost of an unaccept-
however, their use as part of an ADP has not been reported able drop in sensitivity. This is demonstrated by the im-
(22,23). The early identification of patients with AMI is proved low-risk eligibility, but increase in false negative
important, but identifying a true low-risk cohort must cases that would occur by using a TIMI score of 0 or 1
involve the detection of those at risk of a broader group of within this ADP. The TIMI score was derived from a
adverse events, in addition to AMI. high-risk in-patient population to predict the likelihood of
Study limitations. The applicability of the ADP is re- a MACE and to guide therapy, and not for this “rule-out”
stricted to the selected cohort of patients with chest dis- purpose in a low-risk ED population. Yet to date, it is one
comfort suggestive of ACSs that the attending physician of the most validated ACS risk tools available.
2098 Than et al. JACC Vol. 59, No. 23, 2012
Rapid Assessment of Possible Cardiac Chest Pain June 5, 2012:2091–8

Conclusions 9. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007
guidelines for the management of patients with unstable angina/non–ST-
A 2-h ADP using a central laboratory troponin as the sole elevation myocardial infarction. J Am Coll Cardiol 2007;50:652–726.
10. Aroney CN, Dunlevie HL, Bett JH. Use of an accelerated chest pain
biomarker in conjunction with ECG and the TIMI risk assessment protocol in patients at intermediate risk of adverse cardiac
score identified a large group of patients suitable for safe events. Med J Aust 2003;178:370 – 4.
early discharge. These patients are at low risk of a 11. Than M, Cullen L, Reid CM, et al. A 2-h diagnostic protocol to assess
patients with chest pain symptoms in the Asia-Pacific region
short-term MACE. They could therefore have rapid (ASPECT): a prospective observational validation study. Lancet 2011;
discharge with early outpatient follow-up or proceed 377:1077– 84.
more quickly to further in-patients tests, potentially 12. Goodacre SW, Bradburn M, Cross E, Collinson P, Gray A, Hall AS.
The Randomised Assessment of Treatment using Panel Assay of
shortening hospital length of stay. The components Cardiac Markers (RATPAC) trial: a randomised controlled trial of
required for this strategy are already widely available; point-of-care cardiac markers in the emergency department. Heart
therefore, rapid uptake of the ADP is possible by most 2011;97:190 – 6.
13. Lee-Lewandrowski E, Januzzi JL Jr., Grisson R, Mohammed AA,
hospitals with the potential for immediate health service Lewandrowski G, Lewandrowski K. Evaluation of first-draw whole
benefit. blood, point-of-care cardiac markers in the context of the universal
definition of myocardial infarction: a comparison of a multimarker
Acknowledgments panel to troponin alone and to testing in the central laboratory. Arch
Pathol Lab Med 2011;135:459 – 63.
The authors thank Dr. Joanne Deely (who is employed 14. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for
directly by our local research group) for expert medical acute coronary heart disease in epidemiology and clinical research
writing services, the dedicated staff of our research groups in studies. Circulation 2003;108:2543–9.
15. Cullen L, Than M, Brown AF, et al. Comprehensive standardized
Brisbane and Christchurch, and those from the Centre for data definitions for acute coronary syndrome research in emergency
Clinical Research Excellence in Melbourne. The authors departments in Australasia. Emerg Med Australas 2010;22:35–55.
also thank the staff of the respective Emergency Depart- 16. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for
unstable angina/non-ST elevation MI: a method for prognostication
ments for their assistance and support. and therapeutic decision making. JAMA 2000;284:835– 42.
17. Hollander JE, Blomkalns AL, Brogan GX, et al. Standardized
reporting guidelines for studies evaluating risk stratification of ED
Reprint requests and correspondence: Dr. Martin Than, Emer-
patients with potential acute coronary syndromes. Acad Emerg Med
gency Department, Christchurch Hospital, Private Bag 4710, 2004;11:1331– 40.
Christchurch, New Zealand. E-mail: [email protected]. 18. Cannon CP, Battler A, Brindis RG, et al. American College of
Cardiology key data elements and definitions for measuring the clinical
management and outcomes of patients with acute coronary syndromes.
REFERENCES J Am Coll Cardiol 2001;38:2114 –30.
19. Forest RS, Shofer FS, Sease KL, Hollander JE. Assessment of the
1. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. standardized reporting guidelines ECG classification system: the
The health care burden of acute chest pain. Heart 2005;91:229 –30. presenting ECG predicts 30-day outcomes. Ann Emerg Med 2004;
2. Pollack CV Jr., Sites FD, Shofer FS, Sease KL, Hollander JE. 44:206 –12.
Application of the TIMI risk score for unstable angina and non-ST 20. Pitts SR, Niska RW, Xu J. National Hospital Ambulatory Medical
elevation acute coronary syndrome to an unselected emergency depart- Care Survey: 2006 Emergency Department Summary: Division of
ment chest pain population. Acad Emerg Med 2006;13:13– 8. Health Care Statistics 2008. Available at: http://www.cdc.gov/nchs/
3. Chase M, Robey JL, Zogby KE, Sease KL, Shofer FS, Hollander JE. data/nhsr/nhsr007.pdf. Accessed November 12, 2010.
Prospective validation of the Thrombolysis in Myocardial Infarction 21. Body R, Carley S, McDowell G, et al. Rapid exclusion of acute
Risk Score in the emergency department chest pain population. Ann myocardial infarction in patients with undetectable troponin using a
Emerg Med 2006;48:252–9. high-sensitivity assay. J Am Coll Cardiol 2011;58:1332–9.
4. Hollander JE. The continuing search to identify the very-low-risk 22. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of
chest pain patient. Acad Emerg Med 1999;6:979 – 81. copeptin for rapid rule out of acute myocardial infarction. J Am Coll
5. Bernstein SL, Aronsky D, Duseja R, et al. The effect of emergency Cardiol 2009;54:60 – 8.
department crowding on clinically oriented outcomes. Acad Emerg
23. Valle HA, Riesgo LG, Bel MS, Gonzalo FE, Sanchez MS, Oliva LI.
Med 2009;16:1–10.
Clinical assessment of heart-type fatty acid binding protein in early
6. Pollack CV Jr., Antman EM, Hollander JE. 2007 focused update to
diagnosis of acute coronary syndrome. Eur J Emerg Med 2008;15:
the ACC/AHA guidelines for the management of patients with
140 – 4.
ST-segment elevation myocardial infarction: implications for emer-
gency department practice. Ann Emerg Med 2008;52:344 –55.
7. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk Key Words: acute coronary syndromes y acute myocardial infarction y
patients presenting to the emergency department with chest pain: a emergency department y sensitivity and specificity y troponins.
scientific statement from the American Heart Association. Circulation
2010;122:1756 –76. APPENDIX
8. Thygesen K, Alpert JS, White HD, et al. Universal definition of
myocardial infarction. Circulation 2007;116:2634 –53. For the supplemental tables, please see the online version of this article.